Business Context and Reporting Period
Syndax Pharmaceuticals, Inc. (SNDX) filed a Form 8-K on February 26, 2026, to announce financial results for the quarter and full year ended December 31, 2025. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release and corporate presentation furnished as Exhibits 99.1 and 99.2, which are incorporated by reference but not included in the provided text.
Material Changes
The filing does not disclose specific material changes versus prior periods. It serves as a notification that results for the period ended December 31, 2025, have been issued.
Guidance, Outlook, and Risks
The filing references a press release and presentation containing management commentary and outlook but does not include the text of these documents. No specific risks, contingencies, or unusual items are detailed in the 8-K body text provided.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and FY 2025.
- Examine Exhibit 99.2 (Corporate Presentation) for updated clinical trial timelines and financial guidance.
- Verify the company's cash runway and burn rate based on the full-year 2025 results.
- Check for any new regulatory milestones or partnership announcements referenced in the exhibits.